Clinical Trial Update: Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) [Phase 2]

View source ↗

Summary

Phase 2 bridging study of Pittsburgh Compound B and 18F-flutemetamol brain PET imaging in Alzheimer's disease; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Flutemetamol (18F-Flutemetamol)
• Pittsburgh Compound B (Pittsburgh Compound-B)

Snippet

Sponsor: Mayo Clinic | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-11-01